RxDoctor Payments Data

Erinn Hughes, MD

Interventional Cardiology · Bend, ORNPI 1114260635

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (36.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 68.0% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $5,713 and has fallen 97.6% since, to $136 in 2025.

$13,556in general payments, 2019–2025

Across 88 payments — averaging $154.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$9K
  • Abiomed$2K
  • Edwards Lifesciences$1K
  • Penumbra, Inc.$155
  • Chiesi USA, Inc.$132
  • Abbott$127
  • plus $317 from 5 others

What the payments were for

  • Grants$4,93336%
  • Travel & lodging$4,90936%
  • Food & beverage$3,71427%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,556 in reported general payments places this provider in the 70th percentile of 68 interventional cardiology providers in Oregon.

See all interventional cardiology providers in Oregon

Medicare billing

Part B allowed, 2024
$152,944
Medicare patients
485
Services billed
1,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$148,096
JardianceEmpagliflozin14$19,111
Repatha SureclickEvolocumab17$15,330
Metoprolol Succinate218$2,780
Flecainide Acetate56$1,956
Atorvastatin Calcium140$1,896
Ezetimibe49$1,595
Losartan Potassium97$1,251
Rosuvastatin Calcium79$1,151
ClopidogrelClopidogrel Bisulfate114$1,142
Amlodipine Besylate96$753
Potassium Chloride26$734
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$729
Isosorbide Mononitrate ErIsosorbide Mononitrate51$628
Carvedilol40$439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$148,096131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 68 interventional cardiology providers in Oregon.

Other interventional cardiology in Bend

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →